Survival curve showing time to first occurrence of clinically relevant thrombosis by CVC type.</p
Baseline characteristics associated with time to clinically relevant thrombosis (crude hazard ratio ...
<p>Kaplan Meier survival curves for major adverse cardiovascular outcomes by QTcB interval.</p
<p>Fully adjusted survival curves for CVD mortality by HbA1<sub>C</sub> and diabetes category (whole...
<p>Survival curves for (A) time to death from any cause, (B) cardiovascular death, (C) sudden death,...
<p>(a). Overall survival analyzed for cases with or without VTE. (b). Progression-free survival anal...
Comparison of observed, expected and relative survival times after diagnosis.</p
The frequency of thrombosis and the cumulative hierarchy of clinical signs by CVC type (intention to...
Overall survival curves of different diagnosis-to-treatment intervals for the validation cohort by c...
<p>The survival curves for patients in different time durations (A) and with different tumor locatio...
<p>Survival curves of probability of clinical outcomes by: (A) HVPG category; (B) histologic fibrosi...
Depicted are survival curves for all-cause mortality based on the product-limit estimator comparing ...
<p>Overall survival curves of liver cancer patients stratified by different time intervals from diag...
<p>Overall survival curves of liver cancer patients stratified by different time intervals from diag...
<p>Patients with VTE have higher mortality compared to patients without VTE [HR 6.89 (4.29–11.08), p...
<p>Thirty-five of 41 (85.3%) patients with VTE died, 20 (57.1%) within 1 year.</p
Baseline characteristics associated with time to clinically relevant thrombosis (crude hazard ratio ...
<p>Kaplan Meier survival curves for major adverse cardiovascular outcomes by QTcB interval.</p
<p>Fully adjusted survival curves for CVD mortality by HbA1<sub>C</sub> and diabetes category (whole...
<p>Survival curves for (A) time to death from any cause, (B) cardiovascular death, (C) sudden death,...
<p>(a). Overall survival analyzed for cases with or without VTE. (b). Progression-free survival anal...
Comparison of observed, expected and relative survival times after diagnosis.</p
The frequency of thrombosis and the cumulative hierarchy of clinical signs by CVC type (intention to...
Overall survival curves of different diagnosis-to-treatment intervals for the validation cohort by c...
<p>The survival curves for patients in different time durations (A) and with different tumor locatio...
<p>Survival curves of probability of clinical outcomes by: (A) HVPG category; (B) histologic fibrosi...
Depicted are survival curves for all-cause mortality based on the product-limit estimator comparing ...
<p>Overall survival curves of liver cancer patients stratified by different time intervals from diag...
<p>Overall survival curves of liver cancer patients stratified by different time intervals from diag...
<p>Patients with VTE have higher mortality compared to patients without VTE [HR 6.89 (4.29–11.08), p...
<p>Thirty-five of 41 (85.3%) patients with VTE died, 20 (57.1%) within 1 year.</p
Baseline characteristics associated with time to clinically relevant thrombosis (crude hazard ratio ...
<p>Kaplan Meier survival curves for major adverse cardiovascular outcomes by QTcB interval.</p
<p>Fully adjusted survival curves for CVD mortality by HbA1<sub>C</sub> and diabetes category (whole...
DOI
Add to ORKG